Vol. 42 | No. 1 Supplement | January-June 2014 Suppl.Back

Open Access

Suppression of Recurrent Electrical Storms in a Filipino Patient with Brugada Syndrome: A Case Report

Jehan Karen T. Go-Sumalpong, Erdie C. Fadreguilan
Jun 2014 DOI 10.69944/pjc.6270b3fcc4

More Info

Jehan Karen T. Go-Sumalpong, MD, Erdie C. Fadreguilan, MD 

Philippine Heart Center, Quezon City, Philippines 

References
  1. Berne P. Management of patients with Brugada ECG pattern. E-Journal ESC Council for Clinical Cardiology Practice 2009;7. Available at: http://www.escardio.org/communities/councils/ccp/e journal/volume7/Pages/management-brugada-ECG-pattern.aspx#. VBmhIPmSyQw. Accessed on: April 28, 2014. 
  2. Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002;11:337–45. 
  3. Aponte GE. The enigma of “bangungut”. Ann Intern Med 1960 Jun;52:1258-63. 
  4. Albert G, Lee B, Gervacio-Domingo G, Antzelevitch C, Divinagracia R, Jocano F. Unraveling the Enigma of Bangungut: Is Sudden Unexplained Nocturnal Death Syndrome (SUNDS) in the Philippines a Disease Allelic to the Brugada syndrome? Phil J Int Med 2011;49:165-176. 
  5. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293–6. 
  6. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268-72.
  7. Hermida JS, Lemoine JL, Aoun FB, Jarry G, Rey JL, Quiret JC. Prevalence of the brugada syndrome in an apparently healthy population. Am J Cardiol 2000;86:91–4. 
  8. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electro cardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002;105:173-8. 
  9. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005 February 8;111(5):659-70. 
  10. Nademanee K. Prognostic value of electrophysiologic studies in Brugada syndrome. J Am Coll Cardiol 2002;39:1806-7.
  11. Hermida J, Denjoy I, Clerc J. Hydroquinidine Therapy in Brugada syndrome. J Am CollCardiol 2004;43:1853-60. 
  12. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:1301–12. 
  13. Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electro-cardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1420–2. 
  14. Chinushi M, Aizawa Y, Ogawa Y, Shiba M, Takahashi K. Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. J Electrocardiol 1997;30:133–6. 
  15. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731– 1737. 
  16. Rosso R, Glick A, Glikson M, et al. Outcome after implantation of ICD in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J 2008;10:435–439. 
  17. Viskin S, Wilde A, Tan H. Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a prospective registry. Heart Rhythm 2009;6(3):401-404.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.